Eltrombopag (BioDeep_00000178668)

 

Secondary id: BioDeep_00000014995

human metabolite blood metabolite


代谢物信息卡片


3-{2-[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl]diazen-1-yl}-2-hydroxy-[1,1-biphenyl]-3-carboxylic acid

化学式: C25H22N4O4 (442.1640972)
中文名称: 伊屈泼帕
谱图信息: 最多检出来源 Homo sapiens(blood) 8.16%

分子结构信息

SMILES: CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C
InChI: InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,28,30H,1-3H3,(H,32,33)

描述信息

B - Blood and blood forming organs > B02 - Antihemorrhagics > B02B - Vitamin k and other hemostatics
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
C78275 - Agent Affecting Blood or Body Fluid
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS

同义名列表

5 个代谢物同义名

3-{2-[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-2,3-dihydro-1H-pyrazol-4-yl]diazen-1-yl}-2-hydroxy-[1,1-biphenyl]-3-carboxylic acid; 3-{2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-2H-pyrazol-4-yl]diazen-1-yl}-2-hydroxy-[1,1-biphenyl]-3-carboxylic acid; Eltrombopag; Revolade; Promacta



数据库引用编号

12 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Yan Zhang, Jie Li, Xi Li, Qianshuang Geng, Yuqin Xie, Guoxiang Zhang, Mingxia Wei, Yanmei Ma. Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis. Systematic reviews. 2024 Apr; 13(1):101. doi: 10.1186/s13643-024-02515-2. [PMID: 38576005]
  • Zhifa Wang, Nan Wang, Ouyang Juntao, Jingyao Ma, Shuyue Dong, Jinxi Meng, Jingjing Liu, Zhenping Chen, Xiaoling Cheng, Runhui Wu. Long-term eltrombopag in children with chronic immune thrombocytopenia: A single-centre extended real-life observational study in China. British journal of haematology. 2023 Dec; ?(?):. doi: 10.1111/bjh.19253. [PMID: 38087811]
  • Ruixin Li, Ningling Wang, Xingxing Chai, Linhai Yang, Kangkang Liu, Hailong He, Shengyun Lin, Yan Yang, Jinsong Jia, Donghua Zhang, Yuemin Gong, Jinning Shi, Guangsheng He, Jianyong Li. Prolonged use of eltrombopag in patients with severe aplastic anemia in the real world. Clinical and experimental medicine. 2023 Oct; 23(6):2619-2627. doi: 10.1007/s10238-023-00989-3. [PMID: 36645546]
  • Yao Chen, Rui Zhang, Liuqing Yang, Pei Zhang, Feiyun Wang, Guoqiang Lin, Jiange Zhang, Yuying Zhu. Eltrombopag Inhibits Metastasis in Breast Carcinoma by Targeting HuR Protein. International journal of molecular sciences. 2023 Feb; 24(4):. doi: 10.3390/ijms24043164. [PMID: 36834574]
  • Pugazhenthan Thangaraju, Gopinathan Narasimhan, Vijayakumar Arumugam Ramamurthy, Meenalochini Prakash Gurunthalingam, Sree Sudha Tanguturi Yella, Sajitha Venkatesan, Eswaran Thangaraju. Molecular Docking Analysis of Adhatoda vasica with Thromboxane A2 Receptor (TXA2R) (6IIU) and Antiviral Molecules for Possible Dengue Complications. Infectious disorders drug targets. 2023; 23(1):e180722206836. doi: 10.2174/1871526522666220718101544. [PMID: 35850647]
  • Yu-Yan Hwang, Thomas S Y Chan, Florence H Y Chan, Chris W P Lau, Yan-Yan Luk, Grace W N Lau, Ka-Po Chan, Kwan-Hung Leung, Bonnie Kho, June S M Lau, Chi-Kuen Lau, Vivien Mak, Sze-Fai Yip, Shek-Ying Lin, Joycelyn P Y Sim, Yok-Lam Kwong. Eltrombopag as frontline treatment of aplastic anaemia in routine practice: implications on cost and efficacy. Annals of hematology. 2022 Jun; 101(6):1163-1172. doi: 10.1007/s00277-022-04780-4. [PMID: 35412083]
  • Giorgio Maraziti, Cecilia Becattini. Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia. Journal of thrombosis and thrombolysis. 2022 May; 53(4):954-958. doi: 10.1007/s11239-021-02604-2. [PMID: 34797474]
  • Y Chen, Q Zha, F Huang, C Qiao, Y Wang, R Wang, J Y Li, W Y Shen. [The efficacy of eltrombopag plus cyclosporine A in patients with transfusion-dependent non-severe aplastic anemia: a retrospective study from single center]. Zhonghua nei ke za zhi. 2022 Apr; 61(4):409-411. doi: 10.3760/cma.j.cn112138-20210412-00276. [PMID: 35340188]
  • Régis Peffault de Latour, Austin Kulasekararaj, Simona Iacobelli, Sofie R Terwel, Riley Cook, Morag Griffin, Constantijn J M Halkes, Christian Recher, Fiorenza Barraco, Edouard Forcade, Juan-Carlos Vallejo, Beatrice Drexler, Jean-Baptiste Mear, Alexander E Smith, Emanuele Angelucci, Reinier A P Raymakers, Marco R de Groot, Etienne Daguindau, Erfan Nur, Wilma Barcellini, Nigel H Russell, Louis Terriou, Anna-Paola Iori, Ursula La Rocca, Anna Sureda, Isabel Sánchez-Ortega, Blanca Xicoy, Isidro Jarque, James Cavenagh, Flore Sicre de Fontbrune, Serena Marotta, Talha Munir, Jennifer M L Tjon, Suzanne Tavitian, Aline Praire, Laurence Clement, Florence Rabian, Luana Marano, Anita Hill, Elena Palmisani, Petra Muus, Fabiana Cacace, Camilla Frieri, Maria-Teresa van Lint, Jakob R Passweg, Judith C W Marsh, Gérard Socié, Ghulam J Mufti, Carlo Dufour, Antonio M Risitano. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. The New England journal of medicine. 2022 01; 386(1):11-23. doi: 10.1056/nejmoa2109965. [PMID: 34986284]
  • Ruixin Li, Jiongtao Zhou, Zhengyuan Liu, Xi Chen, Qiqiang Long, Yan Yang, Shengyun Lin, Jinsong Jia, Guangsheng He, JianYong Li. Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag. Frontiers in immunology. 2022; 13(?):884312. doi: 10.3389/fimmu.2022.884312. [PMID: 35720405]
  • Yang Gao, Fei Gao, Jimin Shi, Huarui Fu, He Huang, Yanmin Zhao. Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation. Journal of Zhejiang University. Science. B. 2021 Aug; 22(8):695-700. doi: 10.1631/jzus.b2000532. [PMID: 34414703]
  • Izmarie Poventud-Fuentes, Emily Garnett, Jenny Despotovic, Sridevi Devaraj. Interference of eltrombopag with bilirubin measurements on the Vitros 5600 analyzer. Journal of clinical laboratory analysis. 2021 Aug; 35(8):e23796. doi: 10.1002/jcla.23796. [PMID: 34145609]
  • Jinliang Chen, Yichao Xu, Honggang Lou, Bo Jiang, Rong Shao, Dandan Yang, Yin Hu, Zourong Ruan. Pharmacokinetics of Eltrombopag in Healthy Chinese Subjects and Effect of Sex and Genetic Polymorphism on its Pharmacokinetic and Pharmacodynamic Variability. European journal of drug metabolism and pharmacokinetics. 2021 May; 46(3):427-436. doi: 10.1007/s13318-021-00682-4. [PMID: 33779967]
  • Jiayou Zhang, Yabing Wu, Junhui Liu, Shaolin Han, Lijuan Chen, Hui Wang, Yu Peng. A systematic review and meta-analysis of the safety and efficacy of anti-thymocyte globulin combined with eltrombopag in the treatment of severe aplastic anemia. Annals of palliative medicine. 2021 May; 10(5):5549-5560. doi: 10.21037/apm-21-1049. [PMID: 34107711]
  • Naoya Yanagimachi, Naoshi Obara, Mamiko Sakata-Yanagimoto, Shigeru Chiba, Kosuke Doki, Masato Homma. A simple HPLC assay for determining eltrombopag concentration in human serum. Biomedical chromatography : BMC. 2021 May; 35(5):e5049. doi: 10.1002/bmc.5049. [PMID: 33314287]
  • Suchi Anindita Ghosh, Jean Patrick, Kyaw Zin Maw. Acute kidney injury and nephrotic syndrome associated with eltrombopag therapy in chronic idiopathic thrombocytopenic purpura. BMJ case reports. 2021 Apr; 14(4):. doi: 10.1136/bcr-2020-241462. [PMID: 33827880]
  • Anastasia Martynova, Victor Chiu, Melissa Mert, David Hermel, Ilene Ceil Weitz. Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series. Annals of hematology. 2021 Apr; 100(4):933-939. doi: 10.1007/s00277-021-04401-6. [PMID: 33420879]
  • Hanny Al-Samkari, Katayoon Goodarzi. An Eltrombopag Red (Plasma) Alert. Acta haematologica. 2021; 144(2):227-228. doi: 10.1159/000508599. [PMID: 32702690]
  • Alana Vicente, Bhavisha A Patel, Fernanda Gutierrez-Rodrigues, Emma Groarke, Valentina Giudice, Jennifer Lotter, Xingmin Feng, Sachiko Kajigaya, Barbara Weinstein, Evette Barranta, Matthew J Olnes, Ankur R Parikh, Maher Albitar, Colin O Wu, Ruba Shalhoub, Katherine R Calvo, Danielle M Townsley, Phillip Scheinberg, Cynthia E Dunbar, Neal S Young, Thomas Winkler. Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome. Haematologica. 2020 12; 105(12):2785-2794. doi: 10.3324/haematol.2020.249995. [PMID: 33256377]
  • W R Yang, B Han, H Chang, B Y Wu, F K Meng, D X Ji, Y M Li, Z J Zheng, Y Fei, J P Shen, P Hu, X Q Ding, P Zhang, Y Q Wang, F K Zhang. [Efficacy and safety of eltrombopag in aplastic anemia: A multi-center survey in China]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2020 Nov; 41(11):890-895. doi: 10.3760/cma.j.issn.0253-2727.2020.11.002. [PMID: 33333690]
  • Siqin Feng, Xiaodong Luan, Yifei Wang, Hui Wang, Zhiyu Zhang, Yiyang Wang, Zhuang Tian, Meixi Liu, Ying Xiao, Yong Zhao, Ruilin Zhou, Shuyang Zhang. Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2020 11; 85(?):104419. doi: 10.1016/j.meegid.2020.104419. [PMID: 32540428]
  • Timothy H T Cheng, Teresa K C Tsui, Jeffrey S S Kwok, Lydia C W Lit, Elaine Y L Wong, Richard K T Kam, Denis Grote-Koska, Antje Staaden, Hitoshi Okada, Noriko Fuke, Raymond S M Wong, Chi-Kong Li, Michael H M Chan. Comprehensive characterization and resolution of discrepant spectrophotometric bilirubin results in patients on eltrombopag therapy. Clinical chemistry and laboratory medicine. 2020 09; 58(10):1713-1723. doi: 10.1515/cclm-2019-0684. [PMID: 31584871]
  • Lara Wahlster, Nina Weichert-Leahey, Maria Trissal, Rachael F Grace, Vijay G Sankaran. COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation. Pediatric blood & cancer. 2020 09; 67(9):e28382. doi: 10.1002/pbc.28382. [PMID: 32495391]
  • Maria Filippidou, Georgia Avgerinou, Haroula Tsipou, Natalia Tourkantoni, Katerina Katsibardi, Antonia Vlachou, Kleoniki Roka, Elena Solomou, Antonis Kattamis. Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia. British journal of haematology. 2020 08; 190(3):e157-e159. doi: 10.1111/bjh.16766. [PMID: 32529633]
  • Deepthi Sudhakar, Hassan Kamran, Nan Chen, Martha Mims, Ihab Hamzeh. A Sticky Situation: Aortic Valve Thrombus in Patient with Antiphospholipid Antibody Syndrome and Immune Thrombocytopenia. The American journal of medicine. 2020 08; 133(8):e393-e395. doi: 10.1016/j.amjmed.2019.12.040. [PMID: 31987800]
  • Hao-Tai Ko, Li-Hang Hsu, Sheng-Yung Yang, Ying-Lien Chen. Repurposing the thrombopoietin receptor agonist eltrombopag as an anticryptococcal agent. Medical mycology. 2020 Jun; 58(4):493-504. doi: 10.1093/mmy/myz077. [PMID: 31297540]
  • Jowita Frączkiewicz, Dorota Sęga-Pondel, Bernarda Kazanowska, Marek Ussowicz. Eltrombopag Therapy in Children With Rare Disorders Associated With Thrombocytopenia. Journal of pediatric hematology/oncology. 2020 03; 42(2):113-117. doi: 10.1097/mph.0000000000001528. [PMID: 31205222]
  • Shaoxue Ding, Xiaowei Liang, Tian Zhang, Rong Fu. The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure. Journal of immunology research. 2020; 2020(?):1798795. doi: 10.1155/2020/1798795. [PMID: 33123600]
  • N J Ames, J J Barb, A Ranucci, H Kim, S E Mudra, A K Cashion, D M Townsley, R Childs, B J Paster, L L Faller, G R Wallen. The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study. Annals of hematology. 2019 Jun; 98(6):1351-1365. doi: 10.1007/s00277-019-03599-w. [PMID: 30919073]
  • Ezequiel Kutasz, Alejandra Barbieri, Gabriela D'Isa, Agostina Toscano, Carla Chilelli, Virginia Jurado, Eduardo A Chaler. Eltrombopag interferes with the measurement of plasma total bilirubin in pediatric patients in an automated colorimetric method. Clinical chemistry and laboratory medicine. 2019 05; 57(6):e111-e113. doi: 10.1515/cclm-2018-0789. [PMID: 30332387]
  • Katie Atkinson. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura. Clinical journal of oncology nursing. 2019 04; 23(2):212-216. doi: 10.1188/19.cjon.212-216. [PMID: 30880797]
  • George M Rodgers, Amanda L Kurtti, Jeffrey A Gilreath. Are eltrombopag plasma and skin hyperpigmentation related? The eyes have it. American journal of hematology. 2019 03; 94(3):394-395. doi: 10.1002/ajh.25169. [PMID: 30033660]
  • Valentina Giudice, Angélique Biancotto, Zhijie Wu, Foo Cheung, Julián Candia, Giovanna Fantoni, Sachiko Kajigaya, Olga Rios, Danielle Townsley, Xingmin Feng, Neal S Young. Aptamer-based proteomics of serum and plasma in acquired aplastic anemia. Experimental hematology. 2018 12; 68(?):38-50. doi: 10.1016/j.exphem.2018.09.008. [PMID: 30312735]
  • Mary B Wire, Xiaobin Li, Jianping Zhang, William Sallas, Vassilios Aslanis, Taoufik Ouatas. Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia. Clinical pharmacology and therapeutics. 2018 12; 104(6):1199-1207. doi: 10.1002/cpt.1066. [PMID: 29536526]
  • Vassilios Aslanis, Jianping Zhang, Barbara Lomeli, Kai Grosch, Taoufik Ouatas. Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers. Cancer chemotherapy and pharmacology. 2018 11; 82(5):847-855. doi: 10.1007/s00280-018-3677-6. [PMID: 30171280]
  • Lise J Estcourt, Reem Malouf, Carolyn Doree, Marialena Trivella, Sally Hopewell, Janet Birchall. Prophylactic platelet transfusions prior to surgery for people with a low platelet count. The Cochrane database of systematic reviews. 2018 09; 9(?):CD012779. doi: 10.1002/14651858.cd012779.pub2. [PMID: 30221749]
  • Marco Marano, Jessica Serafinelli, Sara Cairoli, Diego Martinelli, Mara Pisani, Giuseppe Palumbo, Maria G Cefalo, Corrado Cecchetti, Matteo Di Nardo, Felicia S Falvella, Bianca M Goffredo. Eltrombopag-Induced Acute Liver Failure in a Pediatric Patient: A Pharmacokinetic and Pharmacogenetic Analysis. Therapeutic drug monitoring. 2018 08; 40(4):386-388. doi: 10.1097/ftd.0000000000000522. [PMID: 29683873]
  • Alessandro Busca, Chiara Dellacasa, Luisa Giaccone, Sara Manetta, Lucia Biale, Laura Godio, Semra Aydin, Moreno Festuccia, Lucia Brunello, Benedetto Bruno. Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 08; 24(8):1765-1770. doi: 10.1016/j.bbmt.2018.04.022. [PMID: 29684566]
  • Etienne Lengline, Bernard Drenou, Pierre Peterlin, Olivier Tournilhac, Julie Abraham, Ana Berceanu, Brigitte Dupriez, Gaelle Guillerm, Emmanuel Raffoux, Flore Sicre de Fontbrune, Lionel Ades, Marie Balsat, Driss Chaoui, Paul Coppo, Selim Corm, Thierry Leblanc, Natacha Maillard, Louis Terriou, Gerard Socié, Regis Peffault de Latour. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica. 2018 02; 103(2):212-220. doi: 10.3324/haematol.2017.176339. [PMID: 29170252]
  • Xin Zhao, Xingmin Feng, Zhijie Wu, Thomas Winkler, Ronan Desmond, Matthew Olnes, Bogdan Dumitriu, Danielle M Townsley, Cynthia E Dunbar, Neal S Young. Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia. Experimental hematology. 2018 02; 58(?):39-43. doi: 10.1016/j.exphem.2017.09.006. [PMID: 28941711]
  • Daniel Valente Neves, Carolina Pinto Vieira, Adriana Rocha, Vera Lucia Lanchote. Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2018; 21(1):236-246. doi: 10.18433/jpps29856. [PMID: 29949502]
  • Moshe Mittelman, Uwe Platzbecker, Boris Afanasyev, Sebastian Grosicki, Raymond S M Wong, Achilles Anagnostopoulos, Benjamin Brenner, Claudio Denzlinger, Giuseppe Rossi, Arnon Nagler, Regina Garcia-Delgado, Maria Socorro O Portella, Zewen Zhu, Dominik Selleslag. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. The Lancet. Haematology. 2018 Jan; 5(1):e34-e43. doi: 10.1016/s2352-3026(17)30228-4. [PMID: 29241762]
  • Ming-Ming Qu, Xue-Na Liu, Xin-Guang Liu, Qi Feng, Yang Liu, Xu Zhang, Shuang Liu, Lei Zhang, Guo-Sheng Li, Yuan-Yuan Zhu, Ming-Yun Lv, Jun Peng, Ming Hou. Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia. Cytokine. 2017 04; 92(?):110-117. doi: 10.1016/j.cyto.2017.01.013. [PMID: 28142109]
  • Renchi Yang, Junmin Li, Jie Jin, Meijuan Huang, Ziqiang Yu, Xiaojun Xu, Xiaohui Zhang, Ming Hou. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. British journal of haematology. 2017 Jan; 176(1):101-110. doi: 10.1111/bjh.14380. [PMID: 27734464]
  • Kay Weng Choy, Nilika Wijeratne, James C G Doery. Eltrombopag: liver toxicity, kidney injury or assay interference?. Pathology. 2016 Dec; 48(7):754-756. doi: 10.1016/j.pathol.2016.07.011. [PMID: 27780601]
  • Ryszard Grenda, Wioletta Jarmużek, Joanna Latoszyńska, Sylwester Prokurat, Jacek Rubik. Eltrombopag (thrombopoietin-receptor agonist) and plasmapheresis as rescue therapy of acute post-renal transplant immune thrombocytopenia in a child with Schimke immuno-osseous dysplasia-case report. Pediatric transplantation. 2016 Dec; 20(8):1148-1151. doi: 10.1111/petr.12828. [PMID: 27671102]
  • Michael Desborough, Andreas V Hadjinicolaou, Anna Chaimani, Marialena Trivella, Paresh Vyas, Carolyn Doree, Sally Hopewell, Simon J Stanworth, Lise J Estcourt. Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review. The Cochrane database of systematic reviews. 2016 Oct; 10(?):CD012055. doi: 10.1002/14651858.cd012055.pub2. [PMID: 27797129]
  • Verena Gounden, Zhen Zhao. Eltrombopag interference in routine chemistry testing. Annals of clinical biochemistry. 2016 Sep; 53(Pt 5):611-4. doi: 10.1177/0004563215609372. [PMID: 26491115]
  • Xin-Guang Liu, Shuang Liu, Qi Feng, Xue-Na Liu, Guo-Sheng Li, Zi Sheng, Peng Chen, Yang Liu, Yu Wei, Xiao-Yuan Dong, Ping Qin, Chengjiang Gao, Chunhong Ma, Lei Zhang, Ming Hou, Jun Peng. Thrombopoietin receptor agonists shift the balance of Fcγ receptors toward inhibitory receptor IIb on monocytes in ITP. Blood. 2016 08; 128(6):852-61. doi: 10.1182/blood-2016-01-690727. [PMID: 27281793]
  • David F Adams, Teresa S Sellers. Eltrombopag: Investigation of Previously Reported Serum Discoloration and Negative Interference on a Total Bilirubin Diazo Method. Archives of pathology & laboratory medicine. 2016 May; 140(5):391-2. doi: 10.5858/arpa.2015-0473-le. [PMID: 27128294]
  • Mohammad I Saleh, Abdullah R Obeidat, Hanan A Anter, Anas A Khanfar. Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection. Clinical and experimental pharmacology & physiology. 2015 Oct; 42(10):1030-5. doi: 10.1111/1440-1681.12451. [PMID: 26173631]
  • Akihito Fujimi, Yusuke Kamihara, Akari Hashimoto, Yuji Kanisawa, Chisa Nakajima, Naotaka Hayasaka, Shota Yamada, Toshinori Okuda, Shinya Minami, Kaoru Ono, Satoshi Iyama, Junji Kato. Identification of anti-thrombopoietin receptor antibody in prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation treated successfully with eltrombopag. International journal of hematology. 2015 Oct; 102(4):471-6. doi: 10.1007/s12185-015-1806-0. [PMID: 25964100]
  • Savino Bruno, Paresh Sewpaul, Maria Luisa Russo, Vincenzo Boccaccio, Piero Luigi Almasio, Edoardo G Giannini. 12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2015 Oct; 47(10):864-8. doi: 10.1016/j.dld.2015.06.006. [PMID: 26187555]
  • Kai Wu, Mita Thapar, Colm Farrell, Siobhan Hayes, Haiyi Guo, Ming Hou, Jianping Zhang. Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia. Clinical therapeutics. 2015 Jul; 37(7):1382-95. doi: 10.1016/j.clinthera.2015.03.024. [PMID: 25929594]
  • Mary Beth Wire, Lei Fang, Azra Hussaini, Joseph F Kleha, Dickens Theodore. Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir. Antimicrobial agents and chemotherapy. 2014 Nov; 58(11):6704-9. doi: 10.1128/aac.03091-14. [PMID: 25155600]
  • Rambabu Maddela, Ramakrishna Gajula, Nageswara Rao Pilli, Sridhar Siddiraju, Srinubabu Maddela, Ajitha Makula. Liquid chromatography-tandem mass spectrometric assay for eltrombopag in 50μL of human plasma: a pharmacokinetic study. Journal of pharmaceutical and biomedical analysis. 2014 Sep; 98(?):68-73. doi: 10.1016/j.jpba.2014.04.028. [PMID: 24887483]
  • Maria Teresa Álvarez Román, Ihosvany Fernández Bello, Elena G Arias-Salgado, Raquel de Paz, Victor Jiménez Yuste, Monica Martín Salces, Nora V Butta. Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopaenia. British journal of clinical pharmacology. 2014 Sep; 78(3):674-6. doi: 10.1111/bcp.12370. [PMID: 24602175]
  • Kamille A West, Susan F Leitman, Willy A Flegel. Transfusion medicine illustrated: Muddy waters in therapeutic plasma exchange. Transfusion. 2014 Sep; 54(9):2157. doi: 10.1111/trf.12601. [PMID: 25212424]
  • M T Alvarez Román, I Fernández Bello, E G Arias-Salgado, M I Rivas Pollmar, V Jiménez Yuste, M Martín Salces, N V Butta. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. Thrombosis and haemostasis. 2014 Jul; 112(1):65-72. doi: 10.1160/th13-10-0873. [PMID: 24500066]
  • Kazuya Takeuchi, Tomoko Sugiura, Kazuki Matsubara, Ren Sato, Takuya Shimizu, Yusuke Masuo, Masato Horikawa, Noritaka Nakamichi, Norihisa Ishiwata, Yukio Kato. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans. Drug metabolism and disposition: the biological fate of chemicals. 2014 Apr; 42(4):726-34. doi: 10.1124/dmd.113.054767. [PMID: 24440960]
  • Shinji Nakao. [Recent issues and prospects of the treatment of aplastic anemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2014 Jan; 55(1):5-11. doi: NULL. [PMID: 24492031]
  • Robert S Makar, Olga S Zhukov, Mervyn A Sahud, David J Kuter. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. American journal of hematology. 2013 Dec; 88(12):1041-4. doi: 10.1002/ajh.23562. [PMID: 23913253]
  • Siobhan Hayes, Paul N Mudd, Daniele Ouellet, Brendan M Johnson, Daphne Williams, Ekaterina Gibiansky. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia. Cancer chemotherapy and pharmacology. 2013 Jun; 71(6):1507-20. doi: 10.1007/s00280-013-2150-9. [PMID: 23564375]
  • Takumi Kawaguchi, Atsumasa Komori, Masataka Seike, Shigetoshi Fujiyama, Hiroshi Watanabe, Masatoshi Tanaka, Shotaro Sakisaka, Makoto Nakamuta, Yutaka Sasaki, Makoto Oketani, Toshihiro Hattori, Koichi Katsura, Michio Sata. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study. Journal of gastroenterology. 2012 Dec; 47(12):1342-51. doi: 10.1007/s00535-012-0600-5. [PMID: 22674141]
  • Shinya Fujita, Takahisa Nakanishi, Hideaki Yoshimura, Masaaki Hotta, Naoto Nakamichi, Takeshi Tamaki, Kazuyoshi Ishii, Tomoki Ito, Shosaku Nomura. TGFβ(1) and sCTLA-4 levels are increased in eltrombopag-exposed patients with ITP. Thrombosis research. 2012 Sep; 130(3):415-9. doi: 10.1016/j.thromres.2012.06.002. [PMID: 22789125]
  • Mary B Wire, Heidi B McLean, Carolyn Pendry, Dickens Theodore, Jung W Park, Bin Peng. Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects. Antimicrobial agents and chemotherapy. 2012 Jun; 56(6):2846-51. doi: 10.1128/aac.05214-11. [PMID: 22391553]
  • Mary Beth Wire, Jennifer Bruce, Jennifer Gauvin, Carolyn J Pendry, Sandra McGuire, Yanwen Qian, Andres Brainsky. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS. Clinical therapeutics. 2012 Mar; 34(3):699-709. doi: 10.1016/j.clinthera.2012.01.011. [PMID: 22336488]
  • Ryuichi Ogawa, Hirotoshi Echizen. Clinically significant drug interactions with antacids: an update. Drugs. 2011 Oct; 71(14):1839-64. doi: 10.2165/11593990-000000000-00000. [PMID: 21942976]
  • Siobhan Hayes, Daniele Ouellet, Jianping Zhang, Mary B Wire, Ekaterina Gibiansky. Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing. Journal of clinical pharmacology. 2011 Oct; 51(10):1403-17. doi: 10.1177/0091270010383019. [PMID: 21148042]
  • Yanli Deng, Armina Madatian, Mary Beth Wire, Carolyn Bowen, Jung Wook Park, Daphne Williams, Bin Peng, Ernest Schubert, Frances Gorycki, Mark Levy, Peter D Gorycki. Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects. Drug metabolism and disposition: the biological fate of chemicals. 2011 Sep; 39(9):1734-46. doi: 10.1124/dmd.111.040170. [PMID: 21646437]
  • Yanli Deng, Martin Rogers, Caroline Sychterz, Kimberly Talley, Yanwen Qian, David Bershas, May Ho, Wei Shi, Emile P Chen, Cosette Serabjit-Singh, Peter D Gorycki. Investigations of hydrazine cleavage of eltrombopag in humans. Drug metabolism and disposition: the biological fate of chemicals. 2011 Sep; 39(9):1747-54. doi: 10.1124/dmd.111.040188. [PMID: 21646438]
  • Alicia J Allred, Carolyn J Bowen, Jung Wook Park, Bin Peng, Daphne D Williams, Mary Beth Wire, Edmund Lee. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. British journal of clinical pharmacology. 2011 Aug; 72(2):321-9. doi: 10.1111/j.1365-2125.2011.03972.x. [PMID: 21434975]
  • Kazuya Takeuchi, Tomoko Sugiura, Saki Umeda, Kazuki Matsubara, Masato Horikawa, Noritaka Nakamichi, David L Silver, Norihisa Ishiwata, Yukio Kato. Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug metabolism and disposition: the biological fate of chemicals. 2011 Jun; 39(6):1088-96. doi: 10.1124/dmd.110.037960. [PMID: 21422191]
  • Sarah J Barsam, Bethan Psaila, Marc Forestier, Lemke K Page, Peter A Sloane, Julia T Geyer, Glynis O Villarica, Mary M Ruisi, Terry B Gernsheimer, Juerg H Beer, James B Bussel. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood. 2011 May; 117(21):5723-32. doi: 10.1182/blood-2010-11-321398. [PMID: 21389318]
  • John W Bauman, Carolyn T Vincent, Bin Peng, Mary B Wire, Daphne D Williams, Jung Wook Park. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics. Journal of clinical pharmacology. 2011 May; 51(5):739-50. doi: 10.1177/0091270010372106. [PMID: 20663991]
  • Gemma Matthys, Jung Wook Park, Sandra McGuire, Mary Beth Wire, Carolyn Bowen, Daphne Williams, Julian Jenkins, Bin Peng. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers. Journal of clinical pharmacology. 2011 Mar; 51(3):301-8. doi: 10.1177/0091270010368677. [PMID: 20418510]
  • C John Sperati, Michael B Streiff. Acute renal failure in a patient with antiphospholipid syndrome and immune thrombocytopenic purpura treated with eltrombopag. American journal of hematology. 2010 Sep; 85(9):724-6. doi: 10.1002/ajh.21789. [PMID: 20652968]
  • Hans Wadenvik, Bob Olsson. Moving towards a new era in the management of chronic immune thrombocytopenia. Annals of hematology. 2010 Jul; 89 Suppl 1(?):87-93. doi: 10.1007/s00277-009-0873-9. [PMID: 20339846]
  • Gemma Matthys, Jung Wook Park, Sandra McGuire, Mary Beth Wire, Jianping Zhang, Carolyn Bowen, Daphne Williams, Julian M Jenkins, Bin Peng. Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects. British journal of clinical pharmacology. 2010 Jul; 70(1):24-33. doi: 10.1111/j.1365-2125.2010.03646.x. [PMID: 20642544]
  • Julian Jenkins, Daphne Williams, Yanli Deng, David A Collins, Valerie S Kitchen. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis. European journal of clinical pharmacology. 2010 Jan; 66(1):67-76. doi: 10.1007/s00228-009-0716-6. [PMID: 19756558]
  • Joseph A Erhardt, Connie L Erickson-Miller, Manuel Aivado, Melanie Abboud, Kodandaram Pillarisetti, John R Toomey. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Experimental hematology. 2009 Sep; 37(9):1030-7. doi: 10.1016/j.exphem.2009.06.011. [PMID: 19631713]
  • Daphne D Williams, Bin Peng, Christine K Bailey, Mary B Wire, Yanli Deng, Jung Wook Park, David A Collins, Shiva G Kapsi, Julian M Jenkins. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clinical therapeutics. 2009 Apr; 31(4):764-76. doi: 10.1016/j.clinthera.2009.04.010. [PMID: 19446149]
  • Lawrence Rice. Treatment of immune thrombocytopenic purpura: focus on eltrombopag. Biologics : targets & therapy. 2009; 3(?):151-7. doi: 10.2147/btt.2009.2984. [PMID: 19707404]
  • S Panzer. New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review. Vox sanguinis. 2008 Jan; 94(1):1-5. doi: 10.1111/j.1423-0410.2007.00999.x. [PMID: 17973895]